Autres langues Hubei Biocause Pharmaceutical Co., Ltd.

Actions

000627

CNE000000F48

Cours en clôture Shenzhen S.E. Autres places de cotation 00:00:00 10/05/2024			Varia. 5j.	Varia. 1 janv.
2,31 ^CNY	0,00%		-2,94%	-18,66%

29/04	Hubei Biocause Pharmaceutical Co. publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI
15/04	Hubei Biocause Pharmaceutical Co. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023	15/01
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.	22/09/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period	14/08/23
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period	12/06/23
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023	22/05/23
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income	16/05/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022	24/04/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%	30/12/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake	20/06/22
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022	24/05/22
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	05/05/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Hubei Biocause Pharmaceutical Co., Ltd.

Actions

000627

CNE000000F48

Autres langues

Filtres